AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02581176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT00877071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC Bead loaded with doxorubicin
Description: LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
Study NCT04022005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide, Rituximab, Gemcitabine,Oxaliplatin
Description: All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy.
Study NCT00570427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Description: Counseling
Study NCT00570427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management
Description: If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
Study NCT01057108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 20 mg BID
Study NCT01057108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 40 mg BID
Study NCT01057108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOSTRAP Chewing Gum
Description: 20 mg TID
Study NCT00468754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pumps
Study NCT01057108 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewing gum
Study NCT02737020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Rhodiola rosea 200mg pill up to four times a day
Study NCT02737020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to four times a day
Study NCT01608087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502
Description: BI 695502 single i.v. infusion
Study NCT01608087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab single i.v. infusion
Study NCT04201158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Capacity
Description: Modified Shuttle Walk Test
Study NCT01895608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation + dual-tasking
Description: Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
Study NCT01895608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard balance rehabilitation
Description: Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
Study NCT01895608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training (speed of processing)
Description: Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
Study NCT01895608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training (general cognition)
Description: General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
Study NCT04183140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary intervention
Description: primary percutaneous coronary intervention via transulnar or transradial access
Study NCT03134534 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: VATS lobectomy
Description: a minimal invasive surgical types for NSCLC: VATS lobectomy
Study NCT03134534 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RATS lobectomy
Description: a minimal invasive surgical types for NSCLC: RATS lobectomy
Study NCT03879603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-WEVVLP073-00-VP
Description: VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
Study NCT03879603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRC-GENMIX083-AL-VP
Description: VRC-GENMIX083-AL-VP is an adjuvant
Study NCT04263298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg Days 0, 14, 28, then every 28 days
Study NCT04263298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oral Product
Description: Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG101
Description: weekly i.v.
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: twice daily (oral)
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: orally on 5 days of a 28 days cycle
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: i.v. every 3 weeks
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: daily orally
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: weekly i.v.
Study NCT03158389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: orally on 21 days of a 28 days cycle
Study NCT01003600 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
Study NCT03648671 — intervention group
Intervention type: DRUG
Intervention: safinamide metansolfonato (12 weeks)
Description: safinamide metansolfonato
Study NCT03648671 — intervention group
Intervention type: DRUG
Intervention: rasagilina mesilato (12 weeks)
Description: rasagilina mesilato
Study NCT04050124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promogran Prisma
Description: Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
Study NCT04050124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) dressings
Description: standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
Study NCT04050124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC) dressings
Description: standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
Study NCT00484562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen delivery system
Description: Standard oxygen tank with pulse dose regulator
Study NCT00544544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: 50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
Study NCT00484562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Homefill oxygen delivery system
Description: Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
Study NCT00484562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helios oxygen delivery system
Description: Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
Study NCT00484562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle oxygen system
Description: portable battery-powered oxygen concentrator delivery system
Study NCT02190032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mallinckrodt endotracheal tube with a modified angle
Description: At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
Study NCT02190032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallinckrodt endobronchial tube with a conventional angle
Description: Inserting a manufacturer-provided conventional-angled tube
Study NCT02078375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: whey protein plus casein protein
Study NCT02078375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate (Placebo)
Description: The twice daily placebo will consist of a carbohydrate and a small amount of protein
Study NCT00762021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SN60AT
Description: Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
Study NCT02078375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise Program
Description: All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
Study NCT02078375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
Study NCT00762021 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN60WF
Description: Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
Study NCT04925596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePrimaPrescribe online educational program
Description: online training program aiming to change general practitioners' benzodiazepine prescription
Study NCT04925596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ComunicaSaudeMental online educational program
Description: online training program aiming to improve general practitioners' communication with mentally ill patients
Study NCT01374802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 400 mg tablet for oral administration
Study NCT01374802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: tablet for oral administration
Study NCT01374802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Study NCT00610701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior pin placement
Description: Anteriorly-placed (front of the leg) femoral external fixator pins
Study NCT00610701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral pin placement
Description: Laterally-placed (side of the leg) femoral external fixator pind
Study NCT02641457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
Study NCT02641457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
Study NCT03267823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: International Normal Ratio (INR)
Description: Blood test for INR using laboratory and point of care methods
Study NCT03317028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
Study NCT03317028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS02 tablet and placebo tablet
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
Study NCT04424875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Description: patients will remove impacted third molar and receive 3 mg melatonin into 2 ml hydroxyethyl cellulose gel 2%
Study NCT04424875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will remove impacted third molar and receive 2 ml hydroxyethyl cellulose gel 2%
Study NCT00507221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days
Study NCT00507221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: At enrollment and 12 months: 25mg/kg X 1
Study NCT00507221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care in Kenya
Description: Current standard of care for HIV patients in Kenya based on WHO guidelines.
Study NCT01233609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: One to four 250mg softgels by mouth daily (dose determined by body weight)
Study NCT01233609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage per subject weight- same schedule as the active comparator
Study NCT01115543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol and calcitriol
Description: The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
Study NCT01115543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol and calcitriol
Description: The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
Study NCT02069574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Study NCT00641173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: treatment with SSRI paroxetine
Study NCT00641173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with placebo
Study NCT04080518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 MG [Forxiga]
Description: 24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
Study NCT04080518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG [Forxiga]
Description: 24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
Study NCT01084317 — intervention group
Intervention type: OTHER
Intervention: medical documentation and telephone interview
Description: medical documentation analysis supplemented by telephone interview conducted with parents of the child
Study NCT00203151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: edratide
Description: 0.5 mg, 1.0 mg, 2.5 mg injection once weekly
Study NCT00203151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: edratide
Description: 0.5 mg, 1.0 mg, 2.5 mg injection once weekly
Study NCT01411722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)
Description: Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
Study NCT00591123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions
Study NCT00591123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
Study NCT00591123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
Study NCT02372864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction (MBSR)
Description: Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
Study NCT03798834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block (FIB)
Description: ultrasound-guided Fascia iliaca block
Study NCT03798834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
Study NCT00549887 — intervention group
Intervention type: DRUG
Intervention: Analog or Human Insulin
Description: prescribed in accordance with usual clinical practice
Study NCT00847990 — intervention group
Intervention type: OTHER
Intervention: Maternal blood screening test for fetal aneuploidy
Description: One blood draw of 20 to 30 mL
Study NCT00278382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00278382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01091896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
Study NCT01091896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
Study NCT04536571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact lens
Description: Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
Study NCT04536571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact lens
Description: Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
Study NCT04536571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact lens
Description: Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
Study NCT04536571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact lens
Description: Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
Study NCT00599547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
Study NCT01567865 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine produced in existing facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
Study NCT01567865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine produced in new facility
Description: Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China